News stories about Entellus Medical (NASDAQ:ENTL) have trended somewhat negative recently, according to Accern Sentiment. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Entellus Medical earned a news sentiment score of 0.00 on Accern’s scale. Accern also assigned media stories about the medical technology company an impact score of 46.9307849047059 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:
Entellus Medical (ENTL) traded up $0.05 during trading hours on Friday, reaching $15.90. The company’s stock had a trading volume of 281,400 shares, compared to its average volume of 123,751. The company has a debt-to-equity ratio of 0.32, a quick ratio of 3.53 and a current ratio of 1.92. Entellus Medical has a 1-year low of $11.47 and a 1-year high of $20.34.
A number of research analysts recently commented on the company. Zacks Investment Research cut Entellus Medical from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. Canaccord Genuity reissued a “hold” rating and issued a $17.00 price target on shares of Entellus Medical in a report on Tuesday, October 17th. Piper Jaffray Companies reissued a “buy” rating and issued a $21.00 price target on shares of Entellus Medical in a report on Tuesday, August 22nd. Finally, BidaskClub raised Entellus Medical from a “hold” rating to a “buy” rating in a report on Saturday, August 19th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $21.17.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally stolen and republished in violation of United States & international copyright and trademark law. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/11/12/entellus-medical-entl-earns-daily-news-impact-rating-of-0-00.html.
In other news, VP Kevin L. Mensink sold 2,500 shares of the business’s stock in a transaction that occurred on Friday, October 20th. The stock was sold at an average price of $19.00, for a total transaction of $47,500.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Timothy B. Petrick sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 4th. The shares were sold at an average price of $20.01, for a total value of $40,020.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 92,150 shares of company stock worth $1,740,652. Corporate insiders own 7.70% of the company’s stock.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.